Impact of electrocautery and hyperthermic intraperitoneal chemotherapy on intestinal microvasculature in a murine model

Figures & data

Table 1. Experimental groups and electrocautery lesions per site.

Experimental groups	Rats (n)	Total number of EC lesions per site				T (°C)	Exposure time (min)
		Ileum		Jejunum
		Pre	Post	Pre	Post
A. Control	10	22	21	20	20	N/A	35
B. Heated D5W	8	19	22	21	18	43	25
C. OXA 460 mg/m^2	4	12	13	12	12	43	25
D. MMC 10 mg/m^2	6	18	17	18	18	43	25
E. MMC 35 mg/m^2	4	12	12	12	12	43	25

EC: electrocautery; T: Injected solution temperature; D5W: dextrose 5%; OXA: oxaliplatin; MMC: mitomycin; N/A: not applicable.

Figure 1. Jejunum sample with cautery lesion under fluorescence camera, after fluorescein injection.

Table 2. Fluorescence reduction and fluorescence of unharmed tissues.

Experimental groups	FR of pre-HIPEC EC lesions (Mean ± SD)	Fluorescence of unharmed tissues (Mean ± SD)
Ileum
A. Control	0.29 ± 0.09	94.08 ± 12.65
B. Heated D5W	0.34 ± 0.07	89.28 ± 13.89
C. OXA 460 mg/m^2	0.44 ± 0.09	95.40 ± 20.22
D. MMC 10 mg/m^2	0.50 ± 0.08	91.08 ± 12.65
E. MMC 35 mg/m^2	0.33 ± 0.19	79.13 ± 15.80
Jejunum
A. Control	0.29 ± 0.08	94.72 ± 18.40
B. Heated D5W	0.26 ± 0.12	95.49 ± 19.65
C. OXA 460 mg/m^2	0.46 ± 0.09	102.80 ± 19.08
D. MMC 10 mg/m^2	0.45 ± 0.08	96.08 ± 19.62
E. MMC 35 mg/m^2	0.29 ± 0.15	83.58 ± 14.22

FR: fluorescence reduction; HIPEC: hyperthermic intraperitoneal chemotherapy; EC: electrocautery; SD: standard deviation; D5W: dextrose 5%; OXA: oxaliplatin; MMC: mitomycin.

Figure 2. Fluorescence reduction (FR) of ileum lesions. Significant difference with oxaliplatin (^#). Significant difference with mitomycin 10 mg/m² (*). D5%: Dextrose 5%; Oxali: Oxaliplatin; Mito 10: Mitomycin 10 mg/m²; Mito 35: Mitomycin 35 mg/m².

Figure 3. Fluorescence of unharmed ileal tissues. Significant difference with mitomycin 35gmg/m² (^$). D5%: Dextrose 5%; Oxali: Oxaliplatin; Mito 10: Mitomycin 10 mg/m²; Mito 35: Mitomycin 35 mg/m².

Figure 4. Fluorescence reduction (FR) of jejunum lesions. Significant difference with oxaliplatin (^#). Significant difference with mitomycin 10 mg/m² (*). D5%: Dextrose 5%; Oxali: Oxaliplatin; Mito 10: Mitomycin 10 mg/m²; Mito 35: Mitomycin 35 mg/m².

Figure 5. Fluorescence of unharmed jejunal tissues. Significant difference with mitomycin 35 mg/m² (^$). D5%: Dextrose 5%; Oxali: Oxaliplatin; Mito 10: Mitomycin 10 mg/m²; Mito 35: Mitomycin 35 mg/m².